Veracyte Appoints Annie McGuire as General Counsel

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–$VCYT—Veracyte, Inc. (Nasdaq: VCYT), a global diagnostics company, today announced that it has appointed Annie McGuire as senior vice president and general counsel, effective immediately. Ms. McGuire will oversee all aspects of the company’s legal functions and will report to Marc Stapley, Veracyte’s chief executive officer.

“We are delighted to welcome Annie to Veracyte,” said Mr. Stapley. “She brings with her significant experience in Fortune 100 and other healthcare companies. Her proven leadership in running global legal operations and serving as a strategic business partner within large and growing companies will be critical to Veracyte’s success as we continue advancing our strategic vision.”

Ms. McGuire joins Veracyte from Rakuten Medical, Inc., a global biotechnology company, where she led all legal functions as general counsel and corporate secretary. Prior to that, Ms. McGuire was vice president, legal at MyoKardia, Inc., a biotechnology company focused on serious cardiovascular disease, where she led the team through MyoKardia’s $13 billion acquisition by Bristol Myers Squibb. Before that, she spent 13 years at Amgen, Inc. where she held various legal and compliance leadership roles, including senior corporate counsel for global commercial operations and employment and executive compensation. Ms. McGuire began her legal career at Proskauer Rose LLP in New York City. She earned her Juris Doctor from New York Law School, Magna Cum Laude and her Bachelor of Science degree from Pace University, Summa Cum Laude.

“I was drawn to Veracyte for its deep commitment to innovation and improving the lives of patients with high-performing, novel tests,” said Ms. McGuire. “I’m thrilled to join the company as it executes against its plan to deliver a broad menu of tests to patients worldwide.”

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions throughout the patient journey. Our growing menu of advanced diagnostic tests help patients avoid risky, costly procedures and interventions, and reduce time to appropriate treatment. Our tests address eight of the 10 most prevalent cancers by incidence in the United States. In addition to making our tests available in the United States through our central laboratories, our exclusive license to a best-in-class diagnostics instrument positions us to deliver our tests to patients worldwide through laboratories that can perform them locally. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Contacts

Tracy Morris

Vice President of Corporate Communications & Investor Relations

650-380-4413

[email protected]